Increasing Access to Biosimilars Act of 2023

Hozzl · 2024-12-21T09:05:54Z

Explore the details of House Bill 1352 Increasing Access to Biosimilars Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/21/2024, 9:05 AM

Summary of Bill HR 1352

Bill 118 hr 1352, also known as the Increasing Access to Biosimilars Act of 2023, aims to improve access to biosimilar medications in the United States. Biosimilars are biological products that are highly similar to, and have no clinically meaningful differences from, existing FDA-approved biologic medications.

The bill seeks to increase competition in the biologics market by streamlining the approval process for biosimilars and reducing barriers to entry for manufacturers. This would help lower costs for patients and increase access to life-saving medications.

Key provisions of the bill include: 1. Allowing biosimilar manufacturers to rely on FDA-approved reference products for certain data, reducing the time and cost of development. 2. Establishing a pathway for interchangeable biosimilars, which can be substituted for the reference product without the intervention of a healthcare provider. 3. Providing incentives for healthcare providers to prescribe biosimilars, such as reimbursement incentives and education programs. 4. Improving transparency and communication between the FDA, manufacturers, and healthcare providers to ensure the safety and efficacy of biosimilars. Overall, the Increasing Access to Biosimilars Act of 2023 aims to promote competition, lower costs, and increase access to biosimilar medications for patients in the United States.

Congressional Summary of HR 1352

Increasing Access to Biosimilars Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1352

Bill HR 1352 is currently in the status of Bill Introduced since March 3, 2023. Bill HR 1352 was introduced during Congress 118 and was introduced to the House on March 3, 2023. Bill HR 1352's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024

Bipartisan Support of Bill HR 1352

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1352

Primary Policy Focus

Health

Potential Impact Areas

- Congressional oversight

- Government studies and investigations

- Health care costs and insurance

- Medicare

- Prescription drugs

Alternate Title(s) of Bill HR 1352

Increasing Access to Biosimilars Act of 2023

To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.